| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 68.30 | 20.5% | 3.0% |
| Total Income | 68.30 | 20.5% | 3.0% |
| Expenditure | 99.58 | 10.8% | 59.9% |
| PBT | -29.65 | 42.6% | 85.4% |
| Net Profit | -31.38 | 41.2% | 84.5% |
| OPM | -45.80% | 51.04pp | |
| NPM | -45.94% | 48.22pp | |
| EPS | -0.19 | 40.6% | 84.8% |
Novavax Reports Q3 2026 Financial Results and Operational Highlights
05 Nov 2026 · 5 Nov, 6:41 pm
Summary
Novavax reported third quarter 2026 total revenue of $68 million, a 3% decrease year-over-year. Product sales saw a substantial 91% increase to $26 million, while licensing, royalties, and other revenue declined by 25%. The company significantly reduced its net loss to $31 million from $202 million in the prior year's quarter. Management raised full-year 2026 guidance for Non-GAAP Adjusted Total Revenue and improved expense guidance, highlighting the $125 million milestone payment received from Sanofi's Phase 3 trial initiation.
Key Highlights
- 1
Novavax reported total revenue of $68 million for the third quarter of 2026, a 3% decrease compared to $70 million in the same period in 2025.
- 2
Product sales increased by 91% to $26 million in Q3 2026 compared to $13 million in Q3 2025, driven by Nuvaxovid supply sales.
- 3
Licensing, royalties and other revenue decreased by 25% to $43 million in Q3 2026, primarily due to a reduction in R&D reimbursement revenue.
- 4
The company raised its full-year 2026 Non-GAAP Adjusted Total Revenue guidance by $145 million to $400 million at the mid-point.
- 5
Novavax improved its GAAP Combined R&D and SG&A expense guidance by $5 million at the mid-point for the full year 2026.
- 6
A $125 million milestone was earned in October 2026 upon Sanofi's launch of a Phase 3 influenza-COVID-19 combination vaccine trial in Europe.
- 7
The net loss for the third quarter of 2026 was $31 million, a significant improvement from a net loss of $202 million in the same period in 2025.
Management Comments
John C. Jacobs
This quarter, we continued to execute across all three pillars of our strategy. Our partner Sanofi initiated their Phase 3 influenza-COVID-19 combination vaccine trial vaccine trial in Europe, triggering a $125 million milestone payment. Our focused R&D efforts are building a growing body of data on what our technology can do in infectious disease, advancing our C. difficile candidate towards the clinic and exploring oncology as a potential new area of application. And we have been doing this while continuing to reduce expenses and operate with financial discipline. Over time, we believe this strategy can build a robust and profitable Novavax, with multiple partners and products, diversified revenue streams and a meaningful impact on global health.
Informational and educational content only. Not investment advice.